Business ❯ Finance ❯ Market Analysis ❯ Analyst Ratings

Stock Performance

Biogen to Buy RayThera for Up to $1 Billion

The acquisition adds small-molecule anti-inflammatory candidates to Biogen’s pipeline with most payments tied to clinical and regulatory milestones.

Citi’s $710 Price Target Sends Applied Materials Stock Higher

Snowflake Rally Shows Investors Will Pay for AI That Drives Today’s Revenue

Robinhood Q1 Preview Signals Crypto Drag, $1.14 Billion Revenue Expected

CoreWeave Shares Jump on $21 Billion Meta Expansion and Anthropic Deal

Rocket Lab Lands $190 Million Hypersonic Test Deal, Lifts Backlog Past $2 Billion

Circle Soars on Clear Street Upgrade as USDC Sets New Highs

Teradyne Stock Jumps on AI-Fueled Q4 Beat and Big Q1 Guidance

Alphabet Overtakes Apple to Become No. 2 by Market Value

Palantir Stock Rebounds as Valuation Fight Intensifies After Sharp November Slide

Janux Plunges on Mixed Phase 1 Prostate Cancer Data for JANX007

Berkshire Hathaway Discloses $4.9 Billion Alphabet Stake, Sending Shares to Record Highs

Scotiabank Initiates Permian Resources Coverage With Outperform Rating, $21 Price Target

Verizon and AT&T Post Q2 Beats With Diverging Subscriber Trends

Circle Shares Pull Back 15% as BIS Questions Stablecoin Future